High Purity Peptides Review: 5 COA Checks

A useful review of a high-purity peptide supplier comes down to five verifiable things: the HPLC area-percent purity and the wavelength it was measured at, the mass spectrometry identity confirmation against the theoretical mass, whether the certificate of analysis carries the same lot number printed on the vial, whether the COA shows the actual chromatogram or only a typed number, and whether net peptide content is disclosed alongside chromatographic purity. Suppliers that publish all five are rare. Most "99% pure" claims in this market are single-wavelength area-percent figures that say nothing about how much of the vial's mass is actually peptide. Everything below explains how to check each item, what the numbers cost, and when the extra documentation is not worth paying for.

The purity number on the label is a chromatogram statistic, not a mass fraction

HPLC purity is reported as area percent: the peak of interest divided by the total integrated peak area, usually at 214 nm, where the peptide backbone amide bond absorbs. A result of 99.2% means the main peak accounts for 99.2% of the UV-absorbing material that eluted during the run.

That leaves several categories of vial contents entirely uncounted:

Counterion — trifluoroacetate from reverse-phase purification, or acetate after salt exchange. Depending on the number of basic residues, this is commonly 5% to 20% of the lyophilized mass, and it does not absorb at 214 nm.
Residual water — lyophilized peptide is hygroscopic. Karl Fischer titration on typical lots returns 3% to 10% water by mass.
Inorganic salts and scavengers carried through from cleavage, invisible at 214 nm because they have no chromophore.
Anything that never came off the column during a 20 to 30 minute gradient, including strongly retained aggregates.

Stack those together and a vial labeled 99% pure by HPLC frequently contains 70% to 85% peptide by mass. That figure, obtained by amino acid analysis or quantitative nitrogen determination, is called net peptide content, and it appears on a minority of COAs in this market.

A purity percentage is a statement about a chromatogram, not about the contents of the vial. Two lots at 99% area purity can differ by 15 percentage points in actual peptide mass.

This matters for any work where the amount of material is a variable rather than an afterthought. If the study design treats vial mass as peptide mass, the error is systematic and invisible — it does not average out across replicates, and it will not show up until someone tries to reconcile results across two lots from different suppliers.

What a defensible certificate of analysis actually contains

A COA worth the paper it is printed on names its own methods. Look for these elements specifically, and treat their absence as the finding:

Column chemistry and dimensions — for example C18, 4.6 × 250 mm, 5 µm, with the mobile phase composition and gradient profile stated.
Detection wavelength, stated explicitly. 214 nm is standard for backbone detection; 280 nm only sees tryptophan, tyrosine, and to a small degree phenylalanine, so a purity figure quoted at 280 nm on a peptide lacking aromatic residues is meaningless.
The chromatogram image itself, with retention time and a visible baseline — not a transcribed percentage. A trace lets a reviewer see shoulder peaks that integration software may have merged into the main peak.
Integration threshold, often 0.05%. Peaks below the cutoff are discarded, and a low-disclosed threshold is a sign of a real method rather than a marketing number.
Mass spectrometry result — observed mass versus theoretical, typically ESI-MS or MALDI-TOF, agreeing within 0.5 Da for the average mass on sequences under about 5 kDa.

Mass spec confirms identity. HPLC estimates purity. Neither substitutes for the other, and a COA presenting only one is answering half the question. A supplier's quality documentation should make both retrievable by lot before purchase rather than after.

Lot traceability is the part most reviews skip

The single most common documentation failure is not a fabricated number — it is a real COA attached to the wrong lot. A supplier runs analysis on lot A-2411, publishes it, then ships lot A-2603 eight months later against the same PDF. Nothing on the certificate is false. It simply does not describe the material in hand.

Checks that take under five minutes:

Compare the lot number printed on the vial label against the lot number in the COA header. If they differ, the COA is a specimen, not a record.
Check the analysis date. A COA dated more than 24 months before the ship date is describing material that has since passed through an unknown storage history.
Confirm the certificate lists a retest or expiration date, not just a manufacture date. Lyophilized material stored at −20 °C is commonly assigned 24 months; at −80 °C, 36 months or longer is defensible. Material held at 2–8 °C should carry a substantially shorter assignment, and a supplier assigning 36 months to refrigerated storage is not tracking stability data.
Ask whether analysis was in-house or third-party. Independent verification through a contract lab runs roughly $300 to $800 per sample for HPLC plus MS — which is why almost no supplier does it on every lot, and why a supplier that does it quarterly and publishes the results is making a real commitment.

Where the money actually goes

Pricing in this category spans a wide range, and the spread is only partly about purity. A 1 mg vial of a common research peptide typically sits between $25 and $60; a 10 mg presentation of the same material often lands between $80 and $200, putting the per-milligram cost somewhere around $8 to $20 at the small end and $8 to $15 at the larger. Bulk and repeat-order pricing through a wholesale arrangement changes the math again.

The cost drivers that are not purity:

Fill accuracy and vial-to-vial consistency, which requires calibrated filling rather than manual aliquoting.
Cold chain in transit — insulated packaging with gel packs adds roughly $15 to $40 per shipment, and overnight service adds more.
Analytical burden per lot, which is a fixed cost amortized over lot size. A supplier running full characterization on a small lot has to price it in.
Documentation and retention — keeping retained samples and archived chromatograms for years is real overhead that never appears as a line item.

A price that is 40% below the market band usually means one of these was skipped, and analytical burden is the cheapest one to skip because the customer rarely audits it.

When this level of scrutiny is not worth it, and who should not buy

This is the part most supplier comparisons leave out.

Method development and instrument qualification work often does not need it. If the material is being used to establish retention time on a new column, tune source parameters, or verify that a detector is responding linearly, a 95% lot at half the price is fully adequate. Paying a premium for 99% and a third-party COA to confirm that a pump is working is wasted budget.

Single-vial purchases rarely justify document review. Three lots of the same peptide from three suppliers, each verified against COAs, is a $400 to $900 exercise before any experiment is run. For a one-off exploratory injection, that overhead exceeds the value of the answer.

High-purity sourcing does not fix a study that lacks its own analytics. A laboratory with no in-house HPLC has no way to confirm that what arrived matches the certificate, and no way to detect degradation after six months in a freezer that cycles. Purchasing to a 99% specification without the capacity to verify it is buying a claim, not a material.

Failure modes that documentation will not catch:

Post-shipment degradation — a COA describes the material at the time of analysis. Peptides containing methionine, cysteine, or N-terminal glutamine can change measurably after repeated freeze-thaw of the stock container, and no certificate anticipates that.
Sequence-correct but structurally wrong material — MS confirms mass. Mass does not distinguish isomers, D/L substitution at a single residue, or scrambled disulfide connectivity in cyclic sequences. Those require chiral analysis or peptide mapping, which almost no supplier runs as standard.
Deamidation products co-eluting with the main peak. Asn→Asp deamidation shifts mass by +0.98 Da and may not resolve on a generic gradient. A 99% peak can contain a meaningful deamidated fraction.
Aggregation in the solid state, which reverse-phase HPLC will not report because the aggregate dissociates under the acidic organic mobile phase.

Anyone whose work depends on ruling out those four should be running their own orthogonal analysis, not selecting a supplier harder.

A practical evaluation sequence

Order the smallest available presentation from two or three candidate suppliers. Request the lot-specific COA before shipment and confirm the lot number matches on arrival. Run an in-house injection under a fixed method and compare the retention time and peak shape against the supplied chromatogram. Ask directly for net peptide content and counterion identity — the response, including a refusal, is diagnostic. Repeat on a second lot three to six months later; lot-to-lot reproducibility is what separates a manufacturer from a repackager, and it cannot be assessed from a single purchase.

All materials discussed here are supplied for laboratory research purposes only under research use only terms, and questions about lot-specific documentation should go through contact with the catalog and lot number in hand.

Supplied strictly for in-vitro laboratory research by qualified researchers and institutions. Not a drug, food, cosmetic or dietary supplement. Not for human or veterinary consumption. Not evaluated by the FDA.